Alexandra Nisipeanu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alexandra nisipeanu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alexandra Nisipeanu Today - Breaking & Trending Today

Myth versus reality. Five misconceptions about background checks in business

Myth versus reality. Five misconceptions about background checks in business
nineoclock.ro - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nineoclock.ro Daily Mail and Mail on Sunday newspapers.

Alexandra Nisipeanu , Alina Badea , Forensic Services , Alexandru Nae , Senior Manager , Senior Associate , Financial Advisory , Deloitte Romania ,

Occupational fraud generates annual losses of several USD trillion globally. How can companies mitigate reputational risks while hiring? - Nine O' Clock - first exclusively daily publication to appear in English language in Romania

Opinion article by Alexandru Nae, Senior Manager, Financial Advisory, and Alexandra Nisipeanu, Senior Associate, Financial Advisory, Deloitte Romania From professional background to culture fit, there are a lot of boxes to be checked during the recruitment process, in order to spot the right candidate for a certain role. However, one of the most important steps ....

Alexandra Nisipeanu , Association Of Certified Fraud Examiners , Global Fraud , Alexandru Nae , Senior Manager , Financial Advisory , Senior Associate , Certified Fraud Examiners , General Inspectorate ,

Janssen: New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM? (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis

Early treatment in multiple sclerosis (MS) with higher-potency therapies can improve long-term patient outcomes1,2 New subgroup analysis of the pivotal Phase 3 OPTIMUM trial shows that MS patients ....

Janssen Cilag Gm , Alexandra Nisipeanu , Jennifer Mcintyre , Prinzj Ponesimod , Janssen Cilag International , None Of The Janssen Pharmaceutical Companies , European Commission , National Multiple Sclerosis Society , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Actelion Pharmaceuticals Ltd , Exchange Commission , Janssen Global Services , Companies Of Johnson , Idorsia Pharmaceuticals Ltd , European Committee , Treatment Research , Multiple Sclerosis , About Multiple Sclerosis , Pharmaceutical Companies , Cardiovascular Metabolism , Infectious Diseases Vaccines , Janssen Cilag , Concerning Forward Looking Statements , Private Securities Litigation Reform Act , Janssen Pharmaceutica ,

Janssen: European Commission approves PONVORYTM ? (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features

(0)
The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod led to a 30.5 percent reduction in annual relapse rate (p1
The OPTIMUM trial is the first of its kind to compare head-to-head two oral disease modifying treatments (DMTs) in RMS
Approval follows more than 10 years of cumulative data from Phase 2 and Phase 3 studies demonstrating ponesimod s efficacy and safety
1,2,3
Approval builds on Janssen s deep-rooted history in neuroscience and reinforces Company commitment to addressing unmet needs for neurological conditions like MS
Janssen, the Pharmaceutical Companies of Johnson Johnson, announced today that the European Commission (EC) has approved PONVORY ?
(ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features. ....

United States , Alexandra Nisipeanu , Gavin Giovannoni , Jennifer Mcintyre , Prinzj Ponesimod , Chris Delorefice , None Of The Janssen Pharmaceutical Companies , European Commission , Americas Committee For Treatment , Sclerosis Association Of America , National Multiple Sclerosis Society , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Actelion Pharmaceuticals Ltd , Exchange Commission , Companies Of Johnson , European Medicines Agency , Idorsia Pharmaceuticals Ltd , Research In Multiple Sclerosis , Pharmaceutical Companies , Professor Gavin Giovannoni , Queen Mary University , About Multiple Sclerosis , Cardiovascular Metabolism , Infectious Diseases Vaccines ,

Janssen Pharmaceutica NV: Janssen Announces Treatment with ERLEADA?(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Janssen Pharmaceutica NV: Janssen Announces Treatment with ERLEADA?(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer
FOR EMEA PHARMACEUTICAL TRADE AND MEDICAL MEDIA ONLY NOT FOR DISTRIBUTION IN BENELUX, SWEDEN AND ITALY
Janssen Pharmaceutica NV (Janssen) announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of apalutamide plus androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) when compared to placebo plus ADT.
1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #11; Rapid Abstract Session: Prostate Cancer, February 11 9:30 PM-10:15 PM CET). ....

United States , Alexandra Nisipeanu , Noah Reymond , Jennifer Mcintyre , Christopher Delorefice , Axel Merseburger , Asia Pacific , American Society Of Clinical Oncology , Monitoring Committee , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Exchange Commission , Companies Of Johnson , European Medicines Agency , American Society , Clinical Oncology , Cancers Symposium , Rapid Abstract Session , Prostate Cancer , New England Journal , Professor Axel Merseburger , North America , Latin America , South America , Independent Data Monitoring Committee , Pharmaceutical Companies ,